We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
OLUMIANT (Eli Lilly Australia Pty Ltd)
Product name
OLUMIANT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
baricitinib
Registration type
EOI
Indication
Alopecia Areata
OLUMIANT is indicated for the treatment of severe alopecia areata (AA) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 Pharmacodynamic properties; Clinical trials).